WO2003027282A1 - Adamts-15, -16, -17, -18 et -19 - Google Patents

Adamts-15, -16, -17, -18 et -19 Download PDF

Info

Publication number
WO2003027282A1
WO2003027282A1 PCT/JP2002/009771 JP0209771W WO03027282A1 WO 2003027282 A1 WO2003027282 A1 WO 2003027282A1 JP 0209771 W JP0209771 W JP 0209771W WO 03027282 A1 WO03027282 A1 WO 03027282A1
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
physiological
clarifying
same
novel
Prior art date
Application number
PCT/JP2002/009771
Other languages
English (en)
Japanese (ja)
Other versions
WO2003027282A9 (fr
Inventor
Santiago Cal Miguel
Alvaro Jesus Obaya Gonzalez
Maria Llamazares Prada
Cecilia Garabaya Fernandez
Carlos Lopez-Otin
Original Assignee
Daiichi Fine Chemical Co., Ltd.
University Of Oviedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200102165A external-priority patent/ES2204250B1/es
Priority claimed from ES200102166A external-priority patent/ES2201874B1/es
Priority claimed from ES200102167A external-priority patent/ES2205989B1/es
Priority claimed from ES200102193A external-priority patent/ES2213428B1/es
Priority claimed from ES200102192A external-priority patent/ES2211256B1/es
Application filed by Daiichi Fine Chemical Co., Ltd., University Of Oviedo filed Critical Daiichi Fine Chemical Co., Ltd.
Publication of WO2003027282A1 publication Critical patent/WO2003027282A1/fr
Publication of WO2003027282A9 publication Critical patent/WO2003027282A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

La recherche de nouvelles protéines de la famille ADAM, impliquant des protéines multifonctionnelles dotées de deux fonctions d'adhésion et de décomposition de protéines extracellulaires et la détection ses propriétés desdites protéines, sont utiles dans l'étude de phénomènes physiologiques et biologiques variés tels que la réponse immunitaire, l'angiogénèse, la coagulation, la cicatrisation, le processus de régénération, l'implantation d'embryons, le développement foetal, l'infiltration de cellules cancéreuses, les métastases, les processus intervenant dans les rhumatismes ou les affections des vaisseaux cardiaques et le processus de dégénération hématologique et nerveuse, et dans la description de processus normaux ou pathologiques. Grâce à une méthode de clonage moléculaire basée sur l'homologie, on obtient de nouveaux gènes appelés ADAMTS-15, -16, -17, -18 ET 19 et des acides nucléiques codant pour ceux-ci. Lesdites protéines peuvent être dosées à l'aide de techniques de modification génique, etc.; et des moyens de determination d'activités physiologiques et biologiques sont disponibles et applicables, par exemple, au diagnostic de phénomènes physiologiques induits par ces protéines, de maladies associées auxdites protéines et à la détermination de leurs causes et à leur prédiction.
PCT/JP2002/009771 2001-09-24 2002-09-24 Adamts-15, -16, -17, -18 et -19 WO2003027282A1 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
ESP200102165 2001-09-24
ESP200102167 2001-09-24
ESP200102166 2001-09-24
ES200102165A ES2204250B1 (es) 2001-09-24 2001-09-24 Procedimiento de identificacion de la proteina humana adamts-16.
ES200102166A ES2201874B1 (es) 2001-09-24 2001-09-24 Procedimiento de identificacion de la proteina humana adamts-17.
ES200102167A ES2205989B1 (es) 2001-09-24 2001-09-24 Procedimiento de identificacion de la proteina humana adamts-15.
ES200102193A ES2213428B1 (es) 2001-09-25 2001-09-25 Procedimiento de identificacion de la proteina humana adamts-19.
ESP200102192 2001-09-25
ESP200102193 2001-09-25
ES200102192A ES2211256B1 (es) 2001-09-28 2001-09-28 Procedimiento de identificacion de la proteina humana adamts-19.

Publications (2)

Publication Number Publication Date
WO2003027282A1 true WO2003027282A1 (fr) 2003-04-03
WO2003027282A9 WO2003027282A9 (fr) 2003-06-12

Family

ID=27514579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009771 WO2003027282A1 (fr) 2001-09-24 2002-09-24 Adamts-15, -16, -17, -18 et -19

Country Status (2)

Country Link
JP (1) JP2003180384A (fr)
WO (1) WO2003027282A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344821A1 (fr) * 2000-12-18 2003-09-17 Yamanouchi Pharmaceutical Co. Ltd. Nouvelle aggrecanase
EP1347048A1 (fr) * 2000-12-25 2003-09-24 Yamanouchi Pharmaceutical Co. Ltd. Nouvelle protease

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034785A1 (fr) * 1999-11-11 2001-05-17 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle metalloprotease presentant une activite aggrecanase
EP1134286A2 (fr) * 2000-03-14 2001-09-19 Pfizer Products Inc. Adamts polypeptides, acides nucléiques les codant et leurs applications
WO2001083782A2 (fr) * 2000-05-04 2001-11-08 Sugen, Inc. Nouvelles proteases
WO2001098468A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
WO2002026949A2 (fr) * 2000-09-29 2002-04-04 Lexicon Genetics Incorporated Nouvelles proteases humaines et polynucleotides les codant
WO2002029026A2 (fr) * 2000-10-04 2002-04-11 Lexicon Genetics Incorporated Proteases humaines et polynucleotides codant pour ces proteases
WO2002031163A1 (fr) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Nouveau polypeptide de la famille adamts et gene codant pour ce polypeptide
WO2002050258A1 (fr) * 2000-12-18 2002-06-27 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle aggrecanase
WO2002051998A1 (fr) * 2000-12-25 2002-07-04 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle protease

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034785A1 (fr) * 1999-11-11 2001-05-17 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle metalloprotease presentant une activite aggrecanase
EP1134286A2 (fr) * 2000-03-14 2001-09-19 Pfizer Products Inc. Adamts polypeptides, acides nucléiques les codant et leurs applications
WO2001083782A2 (fr) * 2000-05-04 2001-11-08 Sugen, Inc. Nouvelles proteases
WO2001098468A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
WO2002026949A2 (fr) * 2000-09-29 2002-04-04 Lexicon Genetics Incorporated Nouvelles proteases humaines et polynucleotides les codant
WO2002029026A2 (fr) * 2000-10-04 2002-04-11 Lexicon Genetics Incorporated Proteases humaines et polynucleotides codant pour ces proteases
WO2002031163A1 (fr) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Nouveau polypeptide de la famille adamts et gene codant pour ce polypeptide
WO2002050258A1 (fr) * 2000-12-18 2002-06-27 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle aggrecanase
WO2002051998A1 (fr) * 2000-12-25 2002-07-04 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle protease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HURSKAINEN T.L. ET AL.: "ADAM-TS5, ADAM-TS6 and ADAM-TD7, novel members of a new family of zinc metalloproteases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 36, 1999, pages 25555 - 25563, XP002158991 *
KUNO K. ET AL.: "Molecular cloning of a gene encoding a new type of metalloprotein-didintegrin family protein with thrombospondin motifs as an inflammation associated gene", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 1, 1997, pages 556 - 562, XP002911275 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344821A1 (fr) * 2000-12-18 2003-09-17 Yamanouchi Pharmaceutical Co. Ltd. Nouvelle aggrecanase
EP1344821A4 (fr) * 2000-12-18 2004-06-09 Yamanouchi Pharma Co Ltd Nouvelle aggrecanase
US7094590B2 (en) 2000-12-18 2006-08-22 Astellas Pharma Inc. Aggrecanase
US7193073B2 (en) 2000-12-18 2007-03-20 Astellas Pharma Inc. Aggrecanase
EP1347048A1 (fr) * 2000-12-25 2003-09-24 Yamanouchi Pharmaceutical Co. Ltd. Nouvelle protease
EP1347048A4 (fr) * 2000-12-25 2004-07-21 Yamanouchi Pharma Co Ltd Nouvelle protease

Also Published As

Publication number Publication date
WO2003027282A9 (fr) 2003-06-12
JP2003180384A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2001018172A3 (fr) Polypeptides de type facteur de croissance des fibroblastes
WO2001034809A3 (fr) Acides nucleiques et proteines de staphylococcus epidermidis
WO1999040189A3 (fr) ADNc CODANT DES PROTEINES SECRETEES
WO2002008284A3 (fr) Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
WO2002000690A3 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
EP1323728A3 (fr) Méthode pour préparer un standard diagnostique pour un motif de transcription génétique
WO1999031236A3 (fr) ADNc PROLONGES POUR PROTEINES SECRETEES
ATE464391T1 (de) Hyaluronidase aus menschlichem plasma
WO1999025825A3 (fr) ADNc ETENDUS POUR PROTEINES SECRETEES
WO2001092308A3 (fr) Polypeptides a noeud de cystines: molecules 'cloaked-2' et leurs utilisations
EP1064403A4 (fr) Modulation antisens de pecam-1
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2001000806A3 (fr) Proteines codant des adn complementaires avec des peptides-signal
CA2281895A1 (fr) Ikb kinases
WO1998006841A3 (fr) Deux proteines humaines du genre nsp
CA2294566A1 (fr) Proteines ikk-.alpha., acides nucleiques et procedes
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
WO2003027282A1 (fr) Adamts-15, -16, -17, -18 et -19
WO1998018822A3 (fr) Nouvelles proteines humaines lim
WO2002010388A3 (fr) Molecules du type recepteur de complement c3b/c4b et utilisations de ces molecules
WO2001085785A3 (fr) Proteine d'interaction avec le domaine ph

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 50/54 AND 52/54, SEQUENCE LISTING, ADDED

122 Ep: pct application non-entry in european phase